INVA — Innoviva Inc. stock price and chart

INVA

$21.28+0.95%

as of close, Oct 20, 2026

☾ AH $21.28 +0.95%

Innoviva Inc.Stock · HealthcareRussell 2000 · 0.05% of IWMNasdaq Composite · 0.006% of ONEQUS Stock Market · 0.002% of VTIRussell 3000 · 0.002% of IWV

PeersMRNALLYMDTUNHJNJTMO

Share this page

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEEEEEEEEEE

20162019202120242026

10.012.014.016.018.020.022.0010.0M20.0M$21.28

2026-10-20

Price$21.28

MA20$21.65

MA50$21.11

Vol2.3M

What would $1,000 invested in INVA be worth today? →

INVA returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $21.28
YTD price return: +6.45%
YTD total return: +6.45%
Next earnings: Nov 4, 2026
Market cap: 1.5B2016-12 1.2B2026-10 1.5B+32.1% over the window
Enterprise value: 1.2B
Shares outstanding: 72.2M2016-06 111.2M2026-06 72.2M-35.0% over the window
52W low: $17.12
52W high: $25.15
From 52W high: -15.39%
From 52W low: +24.30%
52W range: 52%

Volume

Rel volume: 0.53×
30D volume: 913.1K
30D $ vol: 19M

Fundamentals

Sales (ttm): 440M2016-06 93M2026-06 440M+372.9% over the window
Sales/share: $6.092016-06 $0.842026-06 $6.09+627.9% over the window
EPS (ttm): $4.352016-06 $0.162026-06 $4.35+2617.7% over the window
FCF (ttm): 189.4M2016-06 29.3M2026-06 189.4M+547.1% over the window
FCF/share: $2.622016-06 $0.262026-06 $2.62+896.1% over the window
Book value/share: $17.072016-06 -$3.272026-06 $17.07-622.8% over the window
Net margin: 81.19%2016-06 20.2%2026-06 81.2%+302.9% over the window
ROE: 28.97%2018-12 264.6%2026-06 29.0%-89.1% over the window
ROA: 20.98%2016-06 5.0%2026-06 21.0%+323.1% over the window
Debt / equity: 0.21×2018-12 2.492026-06 0.21-91.6% over the window
Current ratio: 16.012016-06 13.022026-06 16.01+23.0% over the window

Growth (CAGR, ttm) · 10Y

Sales: +18.86%2025-06-30 → 2026-06-30370.2M → 440M (+18.8% total)+14.85%2023-06-30 → 2026-06-30290.4M → 440M (+51.5% total)+3.78%2021-06-30 → 2026-06-30365.5M → 440M (+20.4% total)+16.81%2016-06-30 → 2026-06-3093M → 440M (+372.9% total)
Net income: +825.72%2025-06-30 → 2026-06-3038.6M → 357.2M (+824.3% total)+104.67%2023-09-30 → 2026-06-3049.9M → 357.2M (+616.2% total)+6.14%2021-06-30 → 2026-06-30265.2M → 357.2M (+34.7% total)+34.28%2016-06-30 → 2026-06-3018.7M → 357.2M (+1805.4% total)
FCF: -5.45%2025-06-30 → 2026-06-30200.3M → 189.4M (-5.4% total)+28.93%2023-06-30 → 2026-06-3088.4M → 189.4M (+114.4% total)-10.43%2021-06-30 → 2026-06-30328.6M → 189.4M (-42.3% total)+20.53%2016-06-30 → 2026-06-3029.3M → 189.4M (+547.1% total)
Shares: +14.65%2025-06-30 → 2026-06-3063M → 72.2M (+14.6% total)+3.53%2023-06-30 → 2026-06-3065.1M → 72.2M (+11.0% total)+0.78%2021-06-30 → 2026-06-3069.5M → 72.2M (+4.0% total)-4.22%2016-06-30 → 2026-06-30111.2M → 72.2M (-35.0% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +795.42%2025-06-30 → 2026-06-30$0.49 → $4.35 (+794.1% total)+106.62%2023-09-30 → 2026-06-30$0.59 → $4.35 (+635.1% total)+12.60%2021-06-30 → 2026-06-30$2.40 → $4.35 (+81.0% total)+39.14%2016-06-30 → 2026-06-30$0.16 → $4.35 (+2617.7% total)
Sales/share: +3.67%2025-06-30 → 2026-06-30$5.87 → $6.09 (+3.7% total)+10.93%2023-06-30 → 2026-06-30$4.46 → $6.09 (+36.5% total)+2.98%2021-06-30 → 2026-06-30$5.26 → $6.09 (+15.8% total)+21.96%2016-06-30 → 2026-06-30$0.84 → $6.09 (+627.9% total)
FCF/share: -17.53%2025-06-30 → 2026-06-30$3.18 → $2.62 (-17.5% total)+24.53%2023-06-30 → 2026-06-30$1.36 → $2.62 (+93.1% total)-11.12%2021-06-30 → 2026-06-30$4.73 → $2.62 (-44.5% total)+25.85%2016-06-30 → 2026-06-30$0.26 → $2.62 (+896.1% total)
Book value/share: +50.54%2025-06-30 → 2026-06-30$11.34 → $17.07 (+50.5% total)+26.03%2023-06-30 → 2026-06-30$8.53 → $17.07 (+100.2% total)+29.18%2021-06-30 → 2026-06-30$4.75 → $17.07 (+259.7% total)n/a
Dividend/share: -93.97%2019-03-31 → 2020-03-31$0.00 → $0.00 (-94.0% total)-78.09%2017-03-31 → 2020-03-31$0.00 → $0.00 (-98.9% total)n/an/a
Price: +23.67%2025-10-20 → 2026-10-20$17.21 → $21.28 (+23.6% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+18.34%2023-10-20 → 2026-10-20$12.84 → $21.28 (+65.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+5.21%2021-10-20 → 2026-10-20$16.51 → $21.28 (+28.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+7.78%2016-10-19 → 2026-10-20$10.06 → $21.28 (+111.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +23.67%2025-10-20 → 2026-10-20$17.21 → $21.28 (+23.6% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+18.34%2023-10-20 → 2026-10-20$12.84 → $21.28 (+65.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+5.21%2021-10-20 → 2026-10-20$16.51 → $21.28 (+28.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+7.78%2016-10-19 → 2026-10-20$10.06 → $21.28 (+111.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 4.9×2016-12 30.322026-10 4.30-85.8% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 9.5×2016-12 13.132026-10 9.46-28.0% over the window
Fwd P/E: 9.5×
P/S (ttm)Market cap ÷ TTM revenue.: 3.5×2016-12 10.312026-10 3.49-66.1% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 1.2×2016-12 -3.162026-10 1.25-139.4% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 8.1×2016-12 24.992026-10 8.12-67.5% over the window
EV/EBITDA (fy): 7.0×
EV/Sales (ttm): 2.8×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 12.32%2016-09 4.0%2026-06 11.5%+188.5% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 72.2M ÷ 63.0M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -14.65%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-14.65%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($1.3B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -14.65%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($52.8M) ÷ today's market cap ($1.5B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 3.43%2016-09 7.8%2026-06 3.2%-58.7% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $52.8M + TTM dividends $0) ÷ today's market cap ($1.5B). Same caveat as the cash buyback yield.: 3.43%2016-09 7.9%2026-06 3.2%-59.2% over the window

Vs own 10Y history

P/E: 30th
P/OI: 80th
P/S: 45th
P/B: 5th
P/FCF: 69th

Bar = where today’s multiple sits in INVA’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-20#

+0.95%

+2.60%

+0.66%

+0.00%

YTD

+6.45%

+23.65%

+28.89%

Financial statements

Open full INVA financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+11.34%	+3.49%
JNJ	Johnson & Johnson	-3.94%	+2.19%
ABBV	AbbVie Inc.	+9.52%	+2.26%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+11.24%	+3.04%
MRK	Merck & Co. Inc.	+0.97%	+3.25%
NVS	Novartis AG	+9.45%	+2.29%
TMO	Thermo Fisher Scientific Inc.	+5.51%	+1.18%
AMGN	Amgen Inc.	+13.82%	+3.29%

INVA — Innoviva Inc. price, chart and key statistics